Skip to content

comparison between two treatments for allergic conjunctivitis that are continious pouring of castor plants root and leaves with goats milk and triphala decoction for a definite time period.

A comparative study of efficacy of Eranda siddha Aja dugdha parisheka and Triphala kashaya parisheka in the management of simple allergic conjuctivitis .

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/11/016382
Enrollment
52
Registered
2018-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H108- Other conjunctivitis

Interventions

Intervention1: Eranda siddha aja dugdha: Eranda leaf and root is mixed with aja dugdha and heat is given to make medicine by kshirpak kalpana said by sharngdhara Control Intervention1: triphala kasha

Sponsors

CARC Nigadi Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients having sign and symptoms of allergic conjunctivitis will be selected.

Exclusion criteria

Exclusion criteria: 1.congenital anomalies of eye 2.Patients having any other ocular pathology 3.one eyed patients 4.stevens Johnson syndrome 5.patients having any systemic disease

Design outcomes

Primary

MeasureTime frame
To Compare and study the efficacy of Eranda siddha Aja dugdha and Triphala kashaya parisheka in simple Allergic ConjunctivitisTimepoint: 7 Days study followup- 10th and 15th day

Secondary

MeasureTime frame
1.To study the efficacy of Eranda siddha aja dugdha parisheka. 2.To study the efficacy of Triphala kashay parisheka. 3.To study the adverse effect if any. Timepoint: seven days

Countries

India

Contacts

Public ContactDrDipak Shivaji Dhaygude

P.D.E.AS COLLEGE OF AYURVED AND RESEARCH CENTRE,AKURDI PUNE

virkar.chandana@gmail.com9822199107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026